On Tuesday, Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) was -2.06% drop from the session before settling in for the closing price of $15.08. A 52-week range for RDY has been $12.26 – $16.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 19.33%. When this article was written, the company’s average yearly earnings per share was at -0.59%. With a float of $832.07 million, this company’s outstanding shares have now reached $834.46 million.
The extent of productivity of a business whose workforce counts for 27811 workers is very important to gauge. In terms of profitability, gross margin is 58.5%, operating margin of 22.07%, and the pretax margin is 23.59%.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Dr. Reddy’s Laboratories Ltd. ADR stocks. The insider ownership of Dr. Reddy’s Laboratories Ltd. ADR is 0.00%, while institutional ownership is 13.50%. The most recent insider transaction that took place on Jul 29 ’24, was worth 5,390,000.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -0.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.43% during the next five years compared to 19.33% growth over the previous five years of trading.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Trading Performance Indicators
You can see what Dr. Reddy’s Laboratories Ltd. ADR (RDY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.80, a number that is poised to hit 0.21 in the next quarter and is forecasted to reach 0.64 in one year’s time.
Technical Analysis of Dr. Reddy’s Laboratories Ltd. ADR (RDY)
The latest stats from [Dr. Reddy’s Laboratories Ltd. ADR, RDY] show that its last 5-days average volume of 1.27 million was inferior to 1.96 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.03%.
During the past 100 days, Dr. Reddy’s Laboratories Ltd. ADR’s (RDY) raw stochastic average was set at 64.19%, which indicates a significant increase from 3.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was lower than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.70, while its 200-day Moving Average is $14.46. Now, the first resistance to watch is $14.89. This is followed by the second major resistance level at $15.02. The third major resistance level sits at $15.09. If the price goes on to break the first support level at $14.69, it is likely to go to the next support level at $14.62. Assuming the price breaks the second support level, the third support level stands at $14.49.
Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) Key Stats
There are 834,887K outstanding shares of the company, which has a market capitalization of 12.29 billion. As of now, sales total 3,811 M while income totals 663,000 K. Its latest quarter income was 949,760 K while its last quarter net income were 179,850 K.
